218 related articles for article (PubMed ID: 23965755)
1. Loss of PDCD4 contributes to enhanced chemoresistance in Glioblastoma multiforme through de-repression of Bcl-xL translation.
Liwak U; Jordan LE; Von-Holt SD; Singh P; Hanson JE; Lorimer IA; Roncaroli F; Holcik M
Oncotarget; 2013 Sep; 4(9):1365-72. PubMed ID: 23965755
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological inhibition of Bcl-xL sensitizes osteosarcoma to doxorubicin.
Baranski Z; de Jong Y; Ilkova T; Peterse EF; Cleton-Jansen AM; van de Water B; Hogendoorn PC; Bovée JV; Danen EH
Oncotarget; 2015 Nov; 6(34):36113-25. PubMed ID: 26416351
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Bcl-xL by ABT-737 enhances chemotherapy sensitivity in neurofibromatosis type 1-associated malignant peripheral nerve sheath tumor cells.
Lee SJ; Park HJ; Kim YH; Kim BY; Jin HS; Kim HJ; Han JH; Yim H; Jeong SY
Int J Mol Med; 2012 Aug; 30(2):443-50. PubMed ID: 22664653
[TBL] [Abstract][Full Text] [Related]
4. Bcl-xL represents a therapeutic target in Philadelphia negative myeloproliferative neoplasms.
Petiti J; Lo Iacono M; Rosso V; Andreani G; Jovanovski A; Podestà M; Lame D; Gobbi M; Fava C; Saglio G; Frassoni F; Cilloni D
J Cell Mol Med; 2020 Sep; 24(18):10978-10986. PubMed ID: 32790151
[TBL] [Abstract][Full Text] [Related]
5. Combined inhibition of RAC1 and Bcl-2/Bcl-xL synergistically induces glioblastoma cell death through down-regulation of the Usp9X/Mcl-1 axis.
Hlavac M; Dwucet A; Kast RE; Engelke J; Westhoff MA; Siegelin MD; Debatin KM; Wirtz CR; Halatsch ME; Karpel-Massler G
Cell Oncol (Dordr); 2019 Jun; 42(3):287-301. PubMed ID: 30859392
[TBL] [Abstract][Full Text] [Related]
6. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
Witham J; Valenti MR; De-Haven-Brandon AK; Vidot S; Eccles SA; Kaye SB; Richardson A
Clin Cancer Res; 2007 Dec; 13(23):7191-8. PubMed ID: 18056200
[TBL] [Abstract][Full Text] [Related]
7. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
Hari Y; Harashima N; Tajima Y; Harada M
Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
[TBL] [Abstract][Full Text] [Related]
8. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation.
Chen S; Dai Y; Harada H; Dent P; Grant S
Cancer Res; 2007 Jan; 67(2):782-91. PubMed ID: 17234790
[TBL] [Abstract][Full Text] [Related]
9. Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B.
Rooswinkel RW; van de Kooij B; Verheij M; Borst J
Cell Death Dis; 2012 Aug; 3(8):e366. PubMed ID: 22875003
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Bcl-2 family members sensitises soft tissue leiomyosarcomas to chemotherapy.
de Graaff MA; de Rooij MA; van den Akker BE; Gelderblom H; Chibon F; Coindre JM; Marino-Enriquez A; Fletcher JA; Cleton-Jansen AM; Bovée JV
Br J Cancer; 2016 May; 114(11):1219-26. PubMed ID: 27140314
[TBL] [Abstract][Full Text] [Related]
11. p53-dependent regulation of Mcl-1 contributes to synergistic cell death by ionizing radiation and the Bcl-2/Bcl-XL inhibitor ABT-737.
Tagscherer KE; Fassl A; Sinkovic T; Combs SE; Roth W
Apoptosis; 2012 Feb; 17(2):187-99. PubMed ID: 22002102
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Bcl-2 and Bcl-X enhances chemotherapy sensitivity in hepatoblastoma cells.
Lieber J; Kirchner B; Eicher C; Warmann SW; Seitz G; Fuchs J; Armeanu-Ebinger S
Pediatr Blood Cancer; 2010 Dec; 55(6):1089-95. PubMed ID: 20680965
[TBL] [Abstract][Full Text] [Related]
13. TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo.
Karpel-Massler G; Bâ M; Shu C; Halatsch ME; Westhoff MA; Bruce JN; Canoll P; Siegelin MD
Oncotarget; 2015 Nov; 6(34):36456-71. PubMed ID: 26474387
[TBL] [Abstract][Full Text] [Related]
14. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.
Hikita H; Takehara T; Shimizu S; Kodama T; Shigekawa M; Iwase K; Hosui A; Miyagi T; Tatsumi T; Ishida H; Li W; Kanto T; Hiramatsu N; Hayashi N
Hepatology; 2010 Oct; 52(4):1310-21. PubMed ID: 20799354
[TBL] [Abstract][Full Text] [Related]
15. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737.
Tahir SK; Yang X; Anderson MG; Morgan-Lappe SE; Sarthy AV; Chen J; Warner RB; Ng SC; Fesik SW; Elmore SW; Rosenberg SH; Tse C
Cancer Res; 2007 Feb; 67(3):1176-83. PubMed ID: 17283153
[TBL] [Abstract][Full Text] [Related]
16. NF1 deficiency causes Bcl-xL upregulation in Schwann cells derived from neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
Park HJ; Lee SJ; Sohn YB; Jin HS; Han JH; Kim YB; Yim H; Jeong SY
Int J Oncol; 2013 Feb; 42(2):657-66. PubMed ID: 23292448
[TBL] [Abstract][Full Text] [Related]
17. PI3K/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim expression is induced.
Jebahi A; Villedieu M; Pétigny-Lechartier C; Brotin E; Louis MH; Abeilard E; Giffard F; Guercio M; Briand M; Gauduchon P; Lheureux S; Poulain L
Cancer Lett; 2014 Jun; 348(1-2):38-49. PubMed ID: 24650799
[TBL] [Abstract][Full Text] [Related]
18. STAT1 mediated downregulation of the tumor suppressor gene PDCD4, is driven by the atypical cadherin FAT1, in glioblastoma.
Khan MT; Almas M; Malik N; Jalota A; Sharma S; Ali SA; Luthra K; Suri V; Suri A; Basak S; Seth P; Chosdol K; Sinha S
Cell Signal; 2024 Jul; 119():111178. PubMed ID: 38640981
[TBL] [Abstract][Full Text] [Related]
19. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.
Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S
Cancer Res; 2013 Feb; 73(4):1340-51. PubMed ID: 23243017
[TBL] [Abstract][Full Text] [Related]
20. Induction of Noxa sensitizes human colorectal cancer cells expressing Mcl-1 to the small-molecule Bcl-2/Bcl-xL inhibitor, ABT-737.
Okumura K; Huang S; Sinicrope FA
Clin Cancer Res; 2008 Dec; 14(24):8132-42. PubMed ID: 19088028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
